Xenon Pharmaceuticals ROA 2012-2022 | XENE

Current and historical return on assets (ROA) values for Xenon Pharmaceuticals (XENE) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Xenon Pharmaceuticals ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-03-31 $-0.08B $0.56B -19.41%
2021-12-31 $-0.08B $0.57B -21.97%
2021-09-30 $-0.06B $0.26B -25.12%
2021-06-30 $-0.06B $0.28B -24.32%
2021-03-31 $-0.04B $0.29B -16.18%
2020-12-31 $-0.03B $0.19B -13.40%
2020-09-30 $-0.03B $0.20B -13.58%
2020-06-30 $-0.03B $0.21B -15.54%
2020-03-31 $-0.04B $0.24B -25.08%
2019-12-31 $-0.04B $0.15B -35.04%
2019-09-30 $-0.04B $0.10B -35.29%
2019-06-30 $-0.04B $0.11B -36.36%
2019-03-31 $-0.04B $0.12B -36.11%
2018-12-31 $-0.03B $0.12B -36.06%
2018-09-30 $-0.03B $0.13B -44.44%
2018-06-30 $-0.03B $0.07B -53.33%
2018-03-31 $-0.03B $0.04B -58.70%
2017-12-31 $-0.03B $0.05B -59.90%
2017-09-30 $-0.03B $0.05B -50.88%
2017-06-30 $-0.03B $0.05B -45.49%
2017-03-31 $-0.03B $0.06B -43.58%
2016-12-31 $-0.02B $0.07B -35.80%
2016-09-30 $-0.02B $0.07B -33.07%
2016-06-30 $-0.02B $0.06B -27.09%
2016-03-31 $-0.01B $0.06B -14.71%
2015-12-31 $-0.02B $0.06B -22.07%
2015-09-30 $-0.00B $0.07B -3.83%
2015-06-30 $0.01B $0.08B 6.73%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.599B $0.018B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $167.557B 10.19
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.634B 16.78
Biohaven Pharmaceutical Holding (BHVN) United States $10.186B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.637B 0.00
Arcus Biosciences (RCUS) United States $1.751B 44.40
Emergent Biosolutions (EBS) United States $1.570B 6.72
Myovant Sciences (MYOV) United Kingdom $1.212B 0.00
Zymeworks (ZYME) Canada $0.325B 0.00
Gelesis Holdings (GLS) United States $0.111B 0.00
Ambrx Biopharma (AMAM) United States $0.102B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.091B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00